Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines

Drug Metabolism and Disposition

Volumn 35, Issue 5, 2007, Pages 822-828

  Vibet, Sophie ^a,b,c   Mahéo, Karine ^a,b,c   Goré, Jacques ^a,b,c   Dubois, Pierre ^b,d   Bougnoux, Philippe ^a,b,c   Chourpa, Igor ^b,d  

^a CHRU de Tours   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c Institut Fédératif de Recherche 135 Imagerie Fonctionnelle   (France)

^d IFR 135 Imagerie Fonctionnelle   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOCOSAHEXAENOIC ACID; MITOXANTRONE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CHEMOSENSITIZATION; COMPARATIVE STUDY; CYTOTOXICITY; DNA BINDING; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IMAGING; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR INTERACTION; PRIORITY JOURNAL;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; CELL NUCLEUS; CELL SURVIVAL; CYTOSOL; DOCOSAHEXAENOIC ACIDS; FEMALE; FLUORESCENT DYES; HUMANS; INHIBITORY CONCENTRATION 50; MICROSCOPY, CONFOCAL; MITOXANTRONE; MOLECULAR STRUCTURE; REACTIVE OXYGEN SPECIES; RHODAMINE 123; TIME FACTORS;

EID: 34247395030     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013474     Document Type: Article

References (37)

1. Bell DH (1988) Characterization of the fluorescence of the antitumor agent, mitoxantrone. Biochim Biophys Acta 949:132-137.
2. Bruck TB and Harvey PJ (2003) Oxidation of mitoxantrone by lactoperoxidase. Biochim Biophys Acta 1649:154-163.
3. Burns CP, Haugstad BN, Mossman CJ, North JA, and Ingraham LM (1988a) Membrane lipid alteration: effect on cellular uptake of mitoxantrone. Lipids 23:393-397.
4. Burns CP and North JA (1986) Adriamycin transport and sensitivity in fatty acid-modified leukemia cells. Biochim Biophys Acta 888:10-17.
5. Burns CP, North JA, Petersen ES, and Ingraham LM (1988b) Subcellular distribution of doxorubicin: comparison of fatty acid-modified and unmodified cells. Proc Soc Exp Biol Med 188:455-460.
6. Colas S, Germain E, Arab K, Mahéo K, Goupille C, and Bougnoux P (2005) α-Tocopherol suppresses mammary tumor sensitivity to anthracyclines in fish oil-fed rats. Nutr Cancer 51:178-183.
7. Colas S, Paon L, Denis F, Prat M, Louisot P, Hoinard C, Le Floch O, Ogilvie G, and Bougnoux P (2004) Enhanced radiosensitivity of rat autochthonous mammary tumors by dietary docosahexaenoic acid. Int J Cancer 109:449-454.
8. Consoli U, Van NT, Neamati N, Mahadevia R, Beran M, Zhao S, and Andreeff M (1997) Cellular pharmacology of mitoxantrone in P-glycoprotein-positive and -negative human myeloid leukemic cell lines. Leukemia 11:2066-2074.
9. Das U (2002) A radical approach to cancer. Med Sci Monit 8:RA79-92.
10. Das UN (1999) Essential fatty acids, lipid peroxidation and apoptosis. Prostaglandins Leukotrienes Essent Fatty Acids 61:157-163.
11. Dianzani MU (2003) 4-Hydroxynonenal from pathology to physiology. Mol Aspects Med 24:263-272.
12. Feofanov A, Charonov S, Fleury F, Kudelina I, Jardillier JC, and Nabiev I (1999) Confocal spectral imaging analysis of intracellular interactions of mitoxantrone at different phases of the cell cycle. Anticancer Res 19:5341-5348.
13. Feofanov A, Sharonov S, Fleury F, Kudelina I, and Nabiev I (1997a) Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: intracellular accumulation and distribution of monomers, aggregates, naphthoquinoxaline metabolite, and drug-target complexes. Biophys J 73:3328-3336.
14. Feofanov A, Sharonov S, Kudelina I, Fleury F, and Nabiev I (1997b) Localization and molecular interactions of mitoxantrone within living K562 cells as probed by confocal spectral imaging analysis. Biophys J 73:3317-3327.
15. Fox ME and Smith PJ (1995) Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells. Cancer Chemother Pharmacol 35:403-410.
16. Germain E, Chajes V, Cognault S, Lhuillery C, and Bougnoux P (1998) Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation. Int J Cancer 75:578-583.
17. Germain E, Lavandier F, Chajes V, Schubnel V, Bonnet P, Lhuillery C, and Bougnoux P (1999) Dietary n-3 polyunsaturated fatty acids and oxidants increase rat mammary tumor sensitivity to epirubicin without change in cardiac toxicity. Lipids 34 (Suppl):S203.
18. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 57:727-741.
19. Hazlehurst LA, Foley NE, Gleason-Guzman MC, Hacker MP, Cress AE, Greenberger LW, De Jong MC, and Dalton WS (1999) Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res 59:1021-1028.
20. Kellner U, Hutchinson L, Seidel A, Lage H, Danks MK, Dietel M, and Kaufmann SH (1997) Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Int J Cancer 71:817-824.
21. Kolodziejczyk P, Reszka K, and Lown JW (1988) Enzymatic oxidative activation and transformation of the antitumor agent mitoxantrone. Free Radic Biol Med 5:13-25.
22. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, and Bates SE (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113 (Pt 11):2011-2021.
23. Mahéo K, Vibet S, Steghens JP, Dartigeas C, Lehman M, Bougnoux P, and Goré J (2005) Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation. Free Radic Biol Med 39:742-751.
24. Menendez JA, Lupu R, and Colomer R (2005) Exogenous supplementation with ω-3 polyunsaturated fatty acid docosahexaenoic acid (DHA;22:6N-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. Eur J Cancer Prev 14:263-270.
25. Menendez JA, Ropero S, Lupu R, and Colomer R (2004) ω-6 polyunsaturated fatty acid γ-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: relationship to lipid peroxidation and HER-2/neu expression. Oncol Rep 11:1241-1252.
26. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
27. Novak RF and Kharasch ED (1985) Mitoxantrone: propensity for free radical formation and lipid peroxidation - implications for cardiotoxicity. Invest New Drugs 3:95-99.
28. Panousis C, Kettle AJ, and Phillips DR (1995) Myeloperoxidase oxidizes mitoxantrone to metabolites which bind covalently to DNA and RNA. Anticancer Drug Des 10:593-605.
29. Panousis C, Kettle AJ, and Phillips DR (1997) Neutrophil-mediated activation of mitoxantrone to metabolites which form adducts with DNA. Cancer Lett 113:173-178.
30. Reszka K, Kolodziejczyk P, and Lown JW (1986) Horseradish peroxidase-catalyzed oxidation of mitoxantrone: spectrophotometric and electron paramagnetic resonance studies. J Free Radic Biol Med 2:25-32.
31. Rose DP and Connolly JM (1999) ω-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 83:217-244.
32. Shao Y, Pardini L, and Pardini RS (1995) Dietary menhaden oil enhances mitomycin C antitumor activity toward human mammary carcinoma MX-1. Lipids 30:1035-1045.
33. Sharonov S, Chourpa I, Morjani H, Nabiev I, Manfait M, and Feofanov A (1994) Confocal spectral imaging analysis in studies of the spatial distribution of antitumour drugs within living cancer cells. Anal Chim Acta 290:40-47.
34. Smith PJ, Desnoyers R, Blunt N, Giles Y, Patterson LH, and Watson JV (1997) Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation. Cytometry 27:43-53.
35. Smith PJ, Sykes HR, Fox ME, and Furlong IJ (1992) Subcellular distribution of the anticancer drug mitoxantrone in human and drug-resistant murine cells analyzed by flow cytometry and confocal microscopy and its relationship to the induction of DNA damage. Cancer Res 52:4000-4008.
36. Spector AA and Burns CP (1987) Biological and therapeutic potential of membrane lipid modification in tumors. Cancer Res 47:4529-4537.
37. Stoll BA (2002) N-3 fatty acids and lipid peroxidation in breast cancer inhibition. Br J Nutr 87:193-198.